Physician profile
Michael J Park
NPI 1760864037
$3,007.96
in general payments reported to CMS, 2019-2025
15 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $197 · 2021: $872 · 2022: $465 · 2023: $119 · 2024: $853 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $849.02 | 2023-2025 | Ffrct |
| Abbott Laboratories | $544.60 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $387.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $313.76 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $288.13 | 2021-2025 | |
| Abiomed | $251.82 | 2021-2022 | |
| Viiv Healthcare Company | $124.18 | 2024 | Apretude |
| Regeneron Healthcare Solutions, INC. | $56.01 | 2024-2025 | Evkeeza |
| Boston Scientific Corporation | $46.43 | 2021-2022 | |
| Daiichi Sankyo INC. | $41.42 | 2023-2024 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $32.04 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $25.95 | 2020 | |
| Pfizer INC. | $17.84 | 2022 | |
| Genentech USA, INC. | $17.22 | 2023 | Vabysmo |
| Janssen Pharmaceuticals, INC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.